Prevention & lipidsSecondary analysis
Prepregnancy Adiposity, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk in Midlife
- Secondary analysis of the HAPO FUS prospective cohort study
- multinational
- mediation analysis
Authors' conclusion
In this multinational cohort of pregnant individuals, APOs mediated a small proportion of the association between prepregnancy obesity and CVD risk in mid-life.
Study context
- Population
- Pregnant participants aged ≥18 years without prepregnancy hypertension or diabetes, HAPO FUS, followed up 11.6 ± 1.3 years after delivery10.6% prepregnancy obesity
- Participants
- 4,269 participants
- Comparison
- Prepregnancy obesity vs normal prepregnancy body mass index (BMI)
- Primary endpoint
- Proportion of the association between prepregnancy BMI and midlife cardiovascular disease (CVD) risk factors (MAP, triglycerides, HbA1c) mediated by GDM and new-onset HDP
- Follow-up
- 11.6 ± 1.3 years after delivery
Primary result
As reported in the abstract
Midlife CVD risk factors, obesity vs normal BMI, and mediation by APOs · follow-up at mean age 41.7 ± 5.6 years
Obesity vs Normal BMIDifference, mm Hg (95% CI)
MAP
7.0(6.0–8.1)
Obesity vs Normal BMIDifference, mg/dL (95% CI)
triglycerides
28.5(21.9–35.1)
Obesity vs Normal BMIDifference (95% CI)
HbA1c
0.3%(0.2%–0.4%)
- Proportion of obesity–HbA1c association mediated by GDM (partial)
- 24.6% (95% CI: 20.9%-28.4%)
- Proportion of obesity–MAP association mediated by new-onset hypertensive disorders of pregnancy (HDP) (partial)
- 12.4% (95% CI: 10.6%-14.2%)
Further findings
Incidence of adverse pregnancy outcomes (APOs)
- GDM
- 13.8%
- New-onset HDP
- 10.7%
Original publication
Prepregnancy Adiposity, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk in Midlife. J Am Coll Cardiol. Published 22 April 2025. doi:10.1016/j.jacc.2025.02.033
Summarised from the published abstract; every number is checked against it